Last reviewed · How we verify
Compound Kushen Injection
Compound Kushen Injection, marketed by Beijing Zheng Ju Medical Technology Co., Ltd., holds a unique position in the oncology segment as a traditional Chinese medicine. The drug's key strength lies in its composition patent, which is set to expire in 2028, providing a period of market exclusivity. The primary risk is the potential increase in competition following the patent expiry, which could impact market share and revenue.
At a glance
| Generic name | Compound Kushen Injection |
|---|---|
| Also known as | KS injection |
| Sponsor | Beijing Zheng Ju Medical Technology Co., Ltd. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Survival Benefit of Compound Kushen Injection in the Treatment of Advanced Colorectal Cancer (PHASE4)
- Effect of Compound Kushen Injection Combined With Pabolizumab in the Treatment of Cervical Adenocarcinoma (PHASE2)
- Effects of CKI for Oral Mucositis Caused by Radiotherapy for Head and Neck Cancer (PHASE4)
- Post-marketing Safety Surveillance of Compound Kuh-seng Injection: a Registry Study
- The Randomized Controlled Clinical Trial of Kushen Injection (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Compound Kushen Injection CI brief — competitive landscape report
- Compound Kushen Injection updates RSS · CI watch RSS
- Beijing Zheng Ju Medical Technology Co., Ltd. portfolio CI